Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once dai...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Rheum Dis
Autori principali: Keystone, Edward C, Taylor, Peter C, Tanaka, Yoshiya, Gaich, Carol, DeLozier, Amy M, Dudek, Anna, Zamora, Jorge Velasco, Cobos, Jose Arturo Covarrubias, Rooney, Terence, de Bono, Stephanie, Arora, Vipin, Linetzky, Bruno, Weinblatt, Michael E
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2017
Soggetti:
Clinical and Epidemiological Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705852/
https://ncbi.nlm.nih.gov/pubmed/28798049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211259
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi